ADK-918АДК-918
What is it?
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.
Research context
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.
What the studies found
animal · 2023
Mouse pharmacology experiments
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% at the reported 14-day assessment. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
Limit: Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes ↗analytical · 2019
Chemical synthesis and characterization; background pharmacology citations
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
Limit: Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes ↗animal · Year not established
Multiple mouse strains and laboratory immune assays
The programme reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
Limit: OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
Role of neurotropic adamantane-containing compounds in the regulation of immunity ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Experimental adamantane / analogue
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human efficacy findings verified in this update
- Study methods
- —Source-specific animal, chemistry, patent or dissertation evidence
- Independent replication
- —Independent replication not established; translations are not separate experiments
- Source access
- —Access and review depth appear with each linked record
- Safety evidence
- —Human safety and interactions not established; animal activity is not a safe-use recommendation
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Chlodantane, Cyclontane and the ADK research programme ↗
Linked sources
Explore the research map and unresolved leads ↗
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% at the reported 14-day assessment. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
- Population / setting
- Mouse pharmacology experiments
- What was checked
- Originating research institute’s publication record and abstract checked; full tables not reviewed.
Limitations & review scope
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
- An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
- The Russian and English versions are one publication, not independent replication.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes
I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
- Population / setting
- Chemical synthesis and characterization; background pharmacology citations
- What was checked
- Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Limitations & review scope
- Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
- ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Role of neurotropic adamantane-containing compounds in the regulation of immunity
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
· Dissertation author’s abstract; third-party Russian transcription
The programme reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
- Population / setting
- Multiple mouse strains and laboratory immune assays
- What was checked
- Selected source passages checked; complete methods and risk of bias not appraised.
Limitations & review scope
- OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
- Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996
ADK-559/591/676/677 weakly inhibited hepatic monooxygenase activity. ADK-709/790/828/829/910/918 were identified as P450 inducers. This is an enzyme-screening result, not an endurance or clinical-benefit comparison.
- Population / setting
- Mouse hepatic-enzyme screening; 18 adamantane compounds
- What was checked
- Selected source passages checked; complete methods and risk of bias not appraised.
Limitations & review scope
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.